Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADISE: Peginterferon Add-on to NAs in CHB
NCT05671315Recruiting
- Start
- Jul 2019
- Primary completion
- Aug 2023
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms). Primary endpoint: Change of HBsAg level compared to baseline at Week 48. Started Jul 2019; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05671315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671315.